Literature DB >> 9048349

Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study.

A A Hollander1, R J Hene, J Hermans, L A van Es, F J van der Woude.   

Abstract

Prednisone in combination with cyclosporine and/or azathioprine is commonly used after kidney transplantation to prevent graft rejection. Long-term use of prednisone can give rise to multiple side effects and morbidity. This randomized study was conducted to find out if prednisone could be withdrawn in recipients at least 1 yr after kidney transplantation. Eighty-four such recipients of a cadaveric kidney with stable renal function on cyclosporine and prednisone were randomized to continue prednisone (N = 42) or to withdraw prednisone in a 2-month period (N = 42). The main end point was the percentage of successful prednisone withdrawal. Both groups were compared for the incidence of infections and cardiovascular risk factors and for the incidence and cause of deterioration of renal function. All patients had a 14-month follow-up. In 67% (N = 28) of the patients, prednisone could be withdrawn successfully. Acute rejection was the main cause of withdrawal failure (N = 11, 26%). No grafts were lost due to rejection. In the prednisone withdrawal group, a tendency was noted for a lower incidence of infections (difference: 17%; 95% confidence interval [CI]: -4% to 37%). After withdrawal, less antihypertensive drugs were necessary to control hypertension (difference: 0.5 drugs/patient; 95% CI: -0.9 to -0.1) and 35% less patients (23 of 41 versus nine of 42) needed cholesterol-lowering drugs (95% CI: -54% to -15%). A reduction of the frequency of patients with Type II diabetes mellitus was found (difference 10%; 95% CI: -24% to 5%) with a decrease of glycosylated hemoglobin (difference: 0.4 mmol/L; 95% CI: 0.1 to 0.8). Disappearance of moonface was found in 25% of the patients. Elective withdrawal of prednisone > 1 yr after postmortal kidney transplantation can be accomplished safely provided that patients are controlled frequently. Beneficial effects were found regarding hypertension, hypercholesterolemia, hyperglycemia, and appearance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048349     DOI: 10.1681/ASN.V82294

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  10 in total

Review 1.  Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors:  R Moore; D Hernandez; H Valantine
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale.

Authors:  Moro O Salifu; Fasika Tedla; Serhat Aytug; Amir Hayat; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 3.  Challenges in the diagnosis and management of new-onset diabetes after transplantation.

Authors:  Moro O Salifu; Fasika Tedla; Preethi V Murty; Serhat Aytug; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

Review 4.  Cyclosporin-induced hypertension: incidence, pathogenesis and management.

Authors:  S J Taler; S C Textor; V J Canzanello; L Schwartz
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

5.  Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.

Authors:  Chang-Kwon Oh; Su Jin Kim; Ji Hye Kim; Jong Hoon Lee
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

Review 6.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

Review 7.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant.

Authors:  Vijay Shivaswamy; R Brian Stevens; Ramona Zephier; Myhra Zephier; Junfeng Sun; Gerald Groggel; Judi Erickson; Jennifer Larsen
Journal:  Transplantation       Date:  2008-05-15       Impact factor: 4.939

Review 9.  Management of post-transplant diabetes.

Authors:  Ashley Therasse; Amisha Wallia; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2013-02       Impact factor: 4.810

10.  Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials.

Authors:  A K Ali; J Guo; H Ahn; J Shuster
Journal:  Int J Organ Transplant Med       Date:  2011
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.